King Edward Medical University   Report issue

Academic/Hospital Phase 1 Phase 2 Phase 3 Phase 4
Founded: Lahore Pakistan (1860)

Organization Overview

First Clinical Trial
2015
NCT02497326
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

ayesha tariq | chairman /Head of department of pediatrics unit1 K.E medical university/mayo hospital l | Chairman/Head of Department of pediatrics unit 1 K.E. Medical University/Mayo hospital lahore | Dr. Abdul Ahad Jamshaid | Dr Mustahsin Khalil | KEMU Lahore | King Edward Medical University | King Edward Medical University Lahore | King Edward Medical University, Lahore, Pakistan. | Saima Khatoon | Usama Azhar

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Alopecia (Phase 2)

Alopecia Areata (Phase 2)

Appendicitis (Phase 3)

Arthritis (Phase 4)

Arthritis, Rheumatoid (Phase 4)

Asthma (Phase 4)

Burns (Phase 3)

Communicable Diseases (Phase 3)

Congenital Abnormalities (Phase 2)

Critical Illness (Phase 4)

Diabetes Mellitus, Type 2 (Phase 4)

Hyperpigmentation (Phase 2)

Infections (Phase 3)

Insulin Resistance (Phase 4)

Surgical Wound Infection (Phase 3)

Vitamin D Deficiency (Phase 4)

Wounds and Injuries (Phase 1)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 30
  • # of Trial APIs: 42